Welcome to the ePoster Viewing Panel of AICOG 2025

Introduction -- Preterm birth, defined as delivery before 37 weeks, significantly contributes to neonatal mortality and morbidity. Antenatal corticosteroids improve outcomes, but optimal timing for administration remains uncertain. Aim & Objectives: To evaluate the effect of time interval between antenatal corticosteroid administration and delivery on neonatal outcomes in preterm deliveries. Methods: This prospective observational study was conducted in the Departments of Obstetrics, Gynecology, and Neonatology at Pt. B.D. Sharma PGIMS, Rohtak, over one year. It included 200 women with singleton pregnancies at 28-33+6 weeks of gestation, divided into four groups based on the interval between antenatal corticosteroid (ACS) administration and delivery. Group-1: women who delivered within 24-48 hours of ACS administration. Group-2: women who delivered within 2-7 days of ACS administration. Group-3 : women who delivered between 7-14 days after treatment. Group-4: women who delivered after 14 days of administration. Neonatal outcomes included respiratory distress syndrome (RDS), intraventricular hemorrhage (IVH), mortality, and secondary outcomes like necrotising enterocolitis (NEC), hypoglycemia, bronchopulmonary dysplasia and oxygen therapy duration. Results: The majority of women were aged 21-25 years. Mean gestational age ranged from 32.28 to 32.78 weeks, and mean birth weight varied from 1.59 to 1.68 kg. RDS incidence was highest in Group 4. NICU stays and oxygen requirements were longest in Group 4, with significant differences observed in respiratory support durations. Survival rates were highest in Groups 1 and 3. NEC, IVH, PVL, and BPD were rare across all groups, with minimal mortality due to shock or sepsis. Conclusion: Antenatal corticosteroids (ACS) reduce morbidity and mortality in preterm births, though guidelines vary on the ideal ACS-to-birth interval. Our study found no significant differences in Apgar scores, NICU stay, RDS incidence or surfactant use across groups. However, group 4 showed significantly longer and more severe RDS, suggesting ACS effectiveness may decline after 14 days.